Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-In-Class NMT Inhibitor, in Non-Hodgkin's Lymphomas and Solid Tumor Patients
- Written by Newsfile
Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
- Upcoming enrollment of 20-30 patients to begin at the Cross Cancer...